Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2017 (2017), Article ID 6161348, 5 pages
https://doi.org/10.1155/2017/6161348
Case Report

Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma

1Diabetes and Endocrinology Consultants, 2 Crosfield Ave, No. 204, West Nyack, NY 10994, USA
2Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, USA

Correspondence should be addressed to Andreas G. Moraitis; moc.tpecroc@sitiaroma

Received 21 June 2017; Accepted 23 October 2017; Published 19 November 2017

Academic Editor: John Broom

Copyright © 2017 Enzo Ragucci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Kneeman, J. Misdraji, and K. E. Corey, “Secondary causes of nonalcoholic fatty liver disease,” Therapeutic Advances in Gastroenterology, vol. 5, no. 3, pp. 199–207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Angulo, “GI epidemiology: nonalcoholic fatty liver disease,” Alimentary Pharmacology & Therapeutics, vol. 25, no. 8, pp. 883–889, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Ferraù and M. Korbonits, “Metabolic comorbidities in Cushing's syndrome,” European Journal of Endocrinology, vol. 173, no. 4, pp. M133–M157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. G. Rockall, S. A. Sohaib, D. Evans et al., “Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography,” European Journal of Endocrinology, vol. 149, no. 6, pp. 543–548, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. C. P. Woods, J. M. Hazlehurst, and J. W. Tomlinson, “Glucocorticoids and non-alcoholic fatty liver disease,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 154, pp. 94–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. L. L. Gathercole, S. A. Morgan, I. J. Bujalska, D. Hauton, P. M. Stewart, and J. W. Tomlinson, “Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue,” PLoS ONE, vol. 6, no. 10, Article ID e26223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Chalasani, Z. Younossi, and J. E. Lavine, “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Yener, A. Comlekci, S. Ertilav, M. Secil, M. Akarsu, and S. Yesilli, “Non-alcoholic fatty liver disease in subjects with non-functioning adrenal adenomas,” Turkish Journal of Endocrinology and Metabolism, vol. 15, pp. 116–120, 2011. View at Google Scholar
  10. D. P. Macfarlane, P. J. Raubenheimer, T. Preston et al., “Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with type 2 diabetes with and without fatty liver,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 307, no. 7, pp. G760–G768, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Rossi, L. Tauchmanova, A. Luciano et al., “Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 4, pp. 1440–1448, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Terzolo, A. Pia, A. Alì et al., “Adrenal incidentaloma: a new cause of the metabolic syndrome?” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 3, pp. 998–1003, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Zoppini, G. Targher, C. Venturi, C. Zamboni, and M. Muggeo, “Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals,” Clinical Endocrinology, vol. 61, no. 6, pp. 711–715, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Westerbacka, H. Yki-Järvinen, S. Vehkavaara et al., “Body fat distribution and cortisol metabolism in healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 10, pp. 4924–4931, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Targher, L. Bertolini, G. Zoppini, L. Zenari, and G. Falezza, “Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients,” Diabetic Medicine, vol. 22, no. 9, pp. 1146–1150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Targher, L. Bertolini, S. Rodella, G. Zoppini, L. Zenari, and G. Falezza, “Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease,” Clinical Endocrinology, vol. 64, no. 3, pp. 337–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Chiodini, “Clinical review: diagnosis and treatment of subclinical hypercortisolism,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 5, pp. 1223–1236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Fassnacht, W. Arlt, I. Bancos et al., “Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors,” European Journal of Endocrinology, vol. 175, no. 2, pp. G1–G34, 2016. View at Publisher · View at Google Scholar
  19. M. Fleseriu, B. M. K. Biller, J. W. Findling, M. E. Molitch, D. E. Schteingart, and C. Gross, “Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 6, pp. 2039–2049, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Gross, C. M. Blasey, R. L. Roe, K. Allen, T. S. Block, and J. K. Belanoff, “Mifepristone treatment of olanzapine-induced weight gain in healthy men,” Advances in Therapy, vol. 26, no. 10, pp. 959–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Gross, C. M. Blasey, R. L. Roe, and J. K. Belanoff, “Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men,” Obesity, vol. 18, no. 12, pp. 2295–2300, 2010. View at Publisher · View at Google Scholar · View at Scopus